Insider Buying: GSK (LON:GSK) Insider Purchases 8 Shares of Stock

GSK plc (LON:GSK) insider Julie Brown bought 8 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were acquired at an average price of GBX 1,486 per share, for a total transaction of £118.88.

Julie Brown also recently made the following trade(s):

• On Monday, August 11th, Julie Brown purchased 9 shares of GSK stock. The stock was acquired at an average price of GBX 1,408 per share, with a total value of £126.72.

GSK Stock Performance

LON GSK opened at GBX 1,485.98 on Thursday. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK plc has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 1,675. The stock has a 50-day moving average of GBX 1,424.58 and a 200 day moving average of GBX 1,432.24. The stock has a market capitalization of £59.85 billion, a price-to-earnings ratio of 1,796.83, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Sell-side analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GSK shares. Berenberg Bank restated a “hold” rating and set a GBX 1,600 price objective on shares of GSK in a research report on Friday, July 18th. JPMorgan Chase & Co. cut their target price on shares of GSK from GBX 1,460 to GBX 1,400 and set an “underweight” rating for the company in a research note on Monday, August 4th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,450 price target on shares of GSK in a research report on Thursday, July 31st. Finally, Shore Capital reiterated a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.